Article
Cardiac & Cardiovascular Systems
Saha Chatur, Muthiah Vaduganathan, Brian L. Claggett, Finnian R. Mc Causland, Akshay S. Desai, Pardeep S. Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Marc S. Sabatine, Lars Kober, Piotr Ponikowski, Bela Merkely, Magnus Petersson, Anna Maria Langkilde, John J. V. McMurray, Scott D. Solomon
Summary: This study aimed to investigate the safety and efficacy of continuing SGLT2 inhibitors in heart failure (HF) patients with a decline in estimated glomerular filtration rate (eGFR) below a certain threshold. The study found that patients with eGFR decline to <25 mL/min/1.73 m(2) had a higher risk of cardiovascular adverse events, but continuation of dapagliflozin treatment had no excess in safety outcomes and showed benefits in these patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Review
Biology
Panagiotis Theofilis, Evangelos Oikonomou, Konstantinos Tsioufis, Dimitris Tousoulis
Summary: Diabetes mellitus (DM) and heart failure (HF) have a common pathophysiologic background. HF can be caused by various pathways, including inflammation, oxidative stress, endothelial dysfunction, fibrosis, autonomic neuropathy, and alterations in substrate utilization. DM may aggravate myocardial inflammation, fibrosis, autonomic dysfunction, and lipotoxicity. The interaction between DM and HF is critical, and the new treatment approach, SGLT2 inhibitors (SGLT2i), may have beneficial effects in reversing the pathophysiology of these conditions and improving HF outcomes.
Article
Cardiac & Cardiovascular Systems
Tonje Thorvaldsen, Giulia Ferrannini, Linda Mellbin, Lina Benson, Francesco Cosentino, John J. Mcmurray, Ulf Dahlstrom, Lars H. Lund, Gianluigi Savarese
Summary: This study investigated eligibility for dapagliflozin and empagliflozin in a real-world heart failure cohort. The results showed that adopting more practical and label-based selection criteria significantly broadened eligibility. These findings are important for future trial design and clinical application.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Biochemistry & Molecular Biology
Vera Certikova Chabova, Oskar Zakiyanov
Summary: SGLT2 inhibitors have beneficial effects not only in improving diabetes compensation, but also in kidney and cardiovascular outcomes. These benefits are not limited to diabetics, but also found in non-diabetic individuals. The pathophysiological pathways underlying the treatment success have been investigated in clinical and experimental studies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Saverio Muscoli, Francesco Barilla, Rojin Tajmir, Marco Meloni, David Della Morte, Alfonso Bellia, Nicola Di Daniele, Davide Lauro, Aikaterini Andreadi
Summary: SGLT2 inhibitors are a new class of drugs used for treating type 2 diabetes. Recent research has shown their effectiveness in managing heart failure by reducing the risk of cardiovascular events, hospitalization, and mortality. The mechanism behind this effect is still unclear, but it is believed that they lower blood pressure and improve endothelial function. This review focuses on the results of clinical trials investigating the use of SGLT2 inhibitors in heart failure, regardless of the patients' diabetic status. Various SGLT2 inhibitors are compared to explore their potential as a treatment option for patients with reduced ejection fraction and preserved ejection fraction.
Article
Cardiac & Cardiovascular Systems
Kieran F. Docherty, Kirsty McDowell, Paul Welsh, Joanna Osmanska, Inder Anand, Rudolf A. de Boer, Lars Kober, Mikhail N. Kosiborod, Felipe A. Martinez, Eileen Meara, Piotr Ponikowski, Morten Schou, David D. Berg, Marc S. Sabatine, David A. Morrow, Petr Jarolim, Ann Hammarstedt, Mikaela Sjostrand, Anna Maria Langkilde, Scott D. Solomon, Naveed Sattar, Pardeep S. Jhund, John J. V. McMurray
Summary: This study examined the association between baseline CA125 levels and outcomes in patients with chronic ambulatory HF with reduced ejection fraction, and investigated the effect of dapagliflozin. The results show that elevated CA125 levels are an independent predictor of the risk of worsening HF or cardiovascular death, while dapagliflozin reduces the risk of worsening HF or cardiovascular death regardless of baseline CA125 levels.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Chee Hae Kim, In-Chang Hwang, Hong-Mi Choi, Chang Ho Ahn, Yeonyee E. Yoon, Goo-Yeong Cho
Summary: SGLT2i demonstrated more benefits in heart failure and renal outcomes, whereas GLP1RA tended to have more favorable ischemic outcomes.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Biology
Andrew Xanthopoulos, Nikolaos Katsiadas, Spyridon Skoularigkis, Dimitrios E. Magouliotis, Niki Skopeliti, Sotirios Patsilinakos, Alexandros Briasoulis, Filippos Triposkiadis, John Skoularigis
Summary: This study investigated the association between the use of dapagliflozin and cardiac biomarkers as well as cardiac structure in patients with heart failure and diabetes mellitus. The results showed that dapagliflozin was associated with a reduction in cardiac biomarkers and reverse cardiac remodeling, while there were no significant changes in the control group.
Article
Cardiac & Cardiovascular Systems
Liwen Bao, Xiufang Gao, Kun Xie, Yong Li
Summary: Recent cardiovascular outcome trials have shown promising results for SGLT2 inhibitors in preventing heart failure in patients with type 2 diabetes mellitus, even in the presence of risk factors like atherosclerosis. The cardioprotective effects of SGLT2 inhibitors may be attributed to multiple mechanisms including improvement in cardiac and vascular performance, as well as preservation of renal function, which is often impaired in heart failure patients with T2DM.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Carly Adamson, Toru Kondo, Pardeep Jhund, Rudolf A. de Boer, Jose Walter Cabrera Honorio, Brian Claggett, Akshay S. Desai, Marco Antonio Alcocer Gamba, Waleed Al Habeeb, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Anna Maria Langkilde, Daniel Lindholm, Erasmus Bachus, Sheldon E. Litwin, Felipe Martinez, Magnus Petersson, Sanjiv J. Shah, Muthiah Vaduganathan, Pham Nguyen Vinh, Ulrica Wilderang, Scott D. Solomon, John Jv McMurray
Summary: Obesity is common in HFpEF patients and is associated with higher rates of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves cardiovascular outcomes across the spectrum of BMI, leads to greater symptom improvement in patients with obesity, compared with those without, and has the additional benefit of causing modest weight loss.
EUROPEAN HEART JOURNAL
(2022)
Article
Endocrinology & Metabolism
Michael E. Nassif, Sheryl L. Windsor, Fengming Tang, Mansoor Husain, Silvio E. Inzucchi, Darren K. McGuire, Bertram Pitt, Benjamin M. Scirica, Bethany Austin, Michael W. Fong, Shane J. LaRue, Guillermo Umpierrez, Justin Hartupee, Yevgeniy Khariton, Ali O. Malik, Modele O. Ogunniyi, Nanette K. Wenger, Mikhail N. Kosiborod
Summary: This study found that using dapagliflozin can lead to improvement in lung fluid volume in patients with HF, as measured by remote dielectric sensing. This discovery provides a clue to unraveling the mechanisms of benefit of SGLT2 inhibitors in heart failure.
DIABETES OBESITY & METABOLISM
(2021)
Review
Medicine, General & Internal
Chukwuka Elendu, Dependable C. Amaechi, Tochi C. Elendu, Manizha Ashna, Jennifer Ross-Comptis, Sandra O. Ansong, Emmanuel O. Egbunu, Geraldine C. Okafor, Klein A. Jingwa, Akinbayo A. Akintunde, Chidinma M. Ogah, Melissa O. Edeko, Ayodeji V. Ibitoye, Mojetoluwa O. Ogunseye, Chisom E. Alakwe-Ojimba, Eunice K. Omeludike, Chibuike A. Oguine, Rechner N. Afuh, Clinton A. Olawuni, Onyekachukwu R. Ekwem, Boluwatife A. Oyedele, Erica I. Pius, Mercy O. Asekhauno, John A. Ladele, Chinonso B. Okoro, Brandon C. Monika Pouekoua, Joseph S. Adenikinju, Chigozirim M. Agu-ben, Ooreofe Aborisade
Summary: Heart failure and diabetes mellitus are two common and closely related chronic diseases, and their relationship is bidirectional. Understanding the complex interplay between them is crucial for optimizing the management and outcomes of patients with these comorbidities. The shared risk factors and pathophysiological mechanisms are key to the development and progression of both diseases. Comprehensive management strategies targeting both conditions are important for improving patient outcomes.
Article
Endocrinology & Metabolism
Christina Kohlmorgen, Stephen Gerfer, Kathrin Feldmann, Soeren Twarock, Sonja Hartwig, Stefan Lehr, Meike Klier, Irena Krueger, Carolin Helten, Petra Keul, Sabine Kahl, Amin Polzin, Margitta Elvers, Ulrich Floegel, Malte Kelm, Bodo Levkau, Michael Roden, Jens W. Fischer, Maria Grandoch
Summary: The study investigated the effect of SGLT2i dapagliflozin on platelet activation and inflammation in atherogenesis. Results showed that dapagliflozin treatment reduced atherosclerotic lesion development, circulating platelet-leucocyte aggregates, and aortic macrophage infiltration. Additionally, dapagliflozin decreased platelet activation and thrombin generation without affecting bleeding time.
Article
Cardiac & Cardiovascular Systems
Mikhail N. Kosiborod, Ankeet S. Bhatt, Brian L. Claggett, Muthiah Vaduganathan, Ian J. Kulac, Carolyn S. P. Lam, Adrian F. Hernandez, Felipe A. Martinez, Silvio E. Inzucchi, Sanjiv J. Shah, Rudolf A. de Boer, Pardeep S. Jhund, Akshay S. Desai, James C. Fang, Yaling Han, Josep Comin-Colet, Orly Vardeny, Daniel Lindholm, Ulrica Wilderaeng, Olof Bengtsson, John J. V. McMurray, Scott D. Solomon
Summary: In the DELIVER trial, dapagliflozin was found to significantly improve the health status of heart failure patients, as assessed by the Kansas City Cardiomyopathy Questionnaire. The effects were particularly pronounced in patients with higher baseline symptom burden.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Endocrinology & Metabolism
Michelle L. O'Donoghue, Eri T. Kato, Ofri Mosenzon, Sabina A. Murphy, Avivit Cahn, Marisol Herrera, Tsvetalina Tankova, Alena Smahelova, Piera Merlini, Ingrid Gause-Nilsson, Anna Maria Langkilde, Darren K. McGuire, John P. H. Wilding, Larry A. Leiter, Deepak L. Bhatt, Itamar Raz, Marc S. Sabatine, Stephen D. Wiviott
Summary: In this study, it was found that gender did not significantly impact the development of cardiovascular or renal disease in patients with type 2 diabetes treated with dapagliflozin. Furthermore, dapagliflozin showed similar safety and efficacy profiles in women and men.
Article
Education & Educational Research
Gregory Guldner, Jessica Wells, Napatkamon Ayutyanont, Rahul Iyengar, Steven Sprenger, Jason T. Siegel, Rahul Kashyap
Summary: The COVID-19 pandemic has had a transformative impact on the final year of undergraduate medical education, leading to declines in clinical exposures for many students. A survey of recent medical school graduates from the USA revealed that while most participants felt competent in their clinical skills, a significant portion felt below where they should be in areas such as calling consultations, performing procedures, and performing pelvic and rectal exams, as well as safely transitioning care. These perceived deficits highlight the need for evaluation and revised educational approaches in these areas.
MEDICAL EDUCATION ONLINE
(2023)
Article
Medicine, General & Internal
Mariam ElSaban, Gaurang Bhatt, Joanna Lee, Hiren Koshiya, Taha Mansoor, Tanya Amal, Rahul Kashyap
Summary: Neurocritical care is a multidisciplinary field that manages patients with various ailments. This review focuses on the history, timeline, and notable pioneers of neurotrauma-focused neurocritical care. It covers the historical development during early times, the 18th-20th centuries, and modern times, as well as concussions related to warfare and sports. Research in this field is continuously expanding, with several promising innovations on the horizon.
WIENER MEDIZINISCHE WOCHENSCHRIFT
(2023)
Review
Infectious Diseases
Gowthami Sai Kogilathota Jagirdhar, Kaanthi Rama, Shiva Teja Reddy, Harsha Pattnaik, Rakhtan K. K. Qasba, Praveen Reddy Elmati, Rahul Kashyap, Marco Schito, Nitin Gupta
Summary: Acinetobacter baumannii is a multidrug-resistant pathogen commonly associated with nosocomial infections. The resistance profile and ability to produce biofilm make it a complicated organism to treat effectively. Cefoperazone sulbactam is commonly used to treat AB, but the associated data are scarce.
Article
Public, Environmental & Occupational Health
Akshat Banga, Hans Mautong, Razan Alamoudi, Umme Habiba Faisal, Gaurang Bhatt, Tanya Amal, Ayushi Mendiratta, Bhaswanth Bollu, L. V. Simhachalam Kutikuppala, Joanna Lee, Daniel Martin Simadibrata, Ivan Huespe, Aisha Khalid, Mohammed Amir Rais, Ramesh Adhikari, Alisha Lakhani, Piyush Garg, Harsha Pattnaik, Raghu Gandhi, Ramesh Pandit, Faizan Ahmad, Genesis Camacho-Leon, N. Pierre Ciza, Nimsi Barrios, Kelly Meza, Susan Okonkwo, Amuza Dhabuliwo, Hafeez Hamza, Arash Nemat, Mohammad Yasir Essar, Anne Kampa, Rakhtan K. Qasba, Pranjal Sharma, Taru Dutt, Pratikkumar Vekaria, Vikas Bansal, Faisal A. Nawaz, Salim Surani, Rahul Kashyap
Summary: This global cross-sectional study reveals that the majority of healthcare workers (HCWs) have experienced violence, and the incidence either increased or remained the same during the COVID-19 pandemic. This has resulted in decreased job satisfaction.
Article
Education, Scientific Disciplines
Aya Akhras, Mariam ElSaban, Varshini Tamil Selvan, Shaika Zain Alzaabi, Abiola Senok, Nabil Zary, Samuel B. Ho
Summary: This study describes a technologically enhanced course called COVID-19 Rounds and evaluates its impact on student satisfaction, literacy regarding the pandemic, and student engagement. The findings demonstrate that the course was successful in achieving its objectives and encouraging students to participate in research. However, limitations related to the lack of in-person teaching and clinical activities were also identified.
JMIR MEDICAL EDUCATION
(2023)
Review
Medicine, General & Internal
Gowthami Sai Kogilathota Jagirdhar, Harsha Pattnaik, Akshat Banga, Rakhtan K. Qasba, Kaanthi Rama, Shiva Teja Reddy, Anna Carolina Flumignan Bucharles, Rahul Kashyap, Praveen Reddy Elmati, Vikas Bansal, Yatinder Bains, Theodore DaCosta, Salim Surani
Summary: This meta-analysis study found that COVID-19 patients with moderate metabolic-associated fatty liver disease (MAFLD) are more likely to be admitted to the intensive care unit (ICU), require mechanical ventilation, and have more severe disease. Compared to the non-MAFLD group, the MAFLD group had significantly higher rates of ICU admission, need for mechanical ventilation, and disease severity.
MEDICINA-LITHUANIA
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
Joanna Lee, Aditi S. Kothari, Gaurang Bhatt, Navneet Gupta, Ahmed Elsaid Ali, Nadia Najam, Muhammad Mazroua, Taha Mansoor, Tanya Amal, Mariam Elsaban, Rohan Deo, Vikas Bansal, Rahul Kashyap
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
Piyush Garg, Ayushi Mendiratta, Akshat Banga, Anna Carolina Flumignan Bucharles, Maria Victoria Ferreira Piccoli, Balakrishnan Kamaraj, Rakhtan K. Qasba, Vikas Bansal, Rahul Kashyap
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Meeting Abstract
Critical Care Medicine
Cassidy Rodman, Anisa Ali, Lucy Lannon, Ekran Yusuf, Vikas Bansal, Amos Lal, Juan Pablo Domecq Garces, Rahul Kashyap
CRITICAL CARE MEDICINE
(2023)
Meeting Abstract
Critical Care Medicine
Piyush Garg, Niraj Gupta, Gagandeep Singh Wander, Ayushi Mendiratta, Rahul Kashyap
CRITICAL CARE MEDICINE
(2023)
Meeting Abstract
Critical Care Medicine
Kinza Iqbal, Taha Bin Arif, Sawai Rathore, Akshat Banga, Abhishek Bhurwal, Syeda Kisa Batool Naqvi, Muhammad Mehdi, Mitali Salklan, Nikhil Sharma, Amos Lal, Juan Pablo Domecq Garces, Rahul Kashyap, Vikas Bansal
CRITICAL CARE MEDICINE
(2023)
Meeting Abstract
Critical Care Medicine
Tanya Amal, Akshat Banga, Bhaswanth Bollu, Gaurang Bhatt, Umme Habiba Faisal, Salim Surani, Ramesh Pandit, Mohammed Amir Rais, Aisha Khalid, Kelly Meza, L. Simhachalam Kutikuppala, Ivan Huespe, Han Mautong, Hafeez Hamza, Ciza Nshombo Pierre, Piyush Garg, Ayushi Mendiratta, Mohammed Yasir Essar, Faisal Nawaz, Rahul Kashyap
CRITICAL CARE MEDICINE
(2023)
